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Summary We have quantitated the levels of mRNAs in bone marrow samples from patients with multiple
myeloma of the mdrl gene (responsible for the Multidrug Resistance phenotype) and for two of the
glutathione S-transferase gene. GST-2 and GST-3 (which can also inactivate a wide variety of cytotoxic drugs)
and examined the relationship between the levels of expression of these genes and response to subsequent
chemotherapy. From a total of 47 patients. 37 were treated with chemotherapy with 34 evaluable for response.
Twenty-nine of the patients treated had not received any treatment prior to the marrow sampling while eight
had previously received chemotherapy. Patients who failed to respond to initial chemotherapy had significantly
higher levels of mdrl than patients who responded (P = 0.01). In the total myeloma patient data set. mRNA
levels for mdrl and GST-2 were significantly correlated (Spearman rank correlation coefficient (r) = 0.54.
P = 0.0004) as were expression levels of GST-2 with GST-3 (r = 0.43. P = 0.017). GST-3 and mdrl levels were
more weekly associated (r = 0.16. P = 0.4). These data would suggest a significant relationship between failure
of chemotherapy in multiple myeloma patients and increases in expression of the mdrl gene together with
other genes whose products will generate additional mechanisms of resistance to chemotherapeutic agents.
Although a number of cancers initially respond to treatment
with chemotherapeutic agents. many are intrinsically resistant
or ultimately acquire resistance to a variety of drugs. The
phenomenon of multidrug resistance (MDR) which imparts a
collateral resistance to a range of drugs which are struc-
turally and functionally unrelated was first demonstrated in
vitro and was found to be due to the increased expression of
the mdrl gene which encodes a membrane protein. the P-
glycoprotein (p-170) (Kartner et al.. 1983). This multidrug
resistant phenotype is also associated with a decreased accu-
mulation of intracellular drugs due to increased drug efflux
(Fojo et al.. 1985). Multidrug resistant cell lines. particularly
those resistant to high concentration of a drug, usually con-
tain an amplified mdrl gene (Gros et al., 1986). The P-
glycoprotein was also found at higher levels in normal tissue
of kidney, adrenal, liver and colon (Fojo et al., 1987). It is
believed that the mdrl gene might be implicated in the
detoxification of natural compounds since the higher level of
expression occurs mainly in organs involved in this process.
Also, the location of the protein in these organs is on the
lumenal surface of epithelial cells consistent with such an
export function (Thiebaut et al., 1987). However, mammalian
cells possess a number of additional pathways for coping
with xenobiotics. Other major pathways include the Gluta-
thione S-Transferases, Glutathione Peroxidase, and the
diverse group of P450 enzymes which can detoxify many
chemically unrelated compounds (Meister, 1988). Any coor-
dinate overexpression of these additional pathways which
have evolved to respond to chemical insults to the cell will
also have a significant effect on the response of tumour cells
to chemotherapeutic agents.
Multiple myeloma has a response rate of 50-70% to initial
chemotherapy either with an alkylating agent (melphalan or
cyclophosphamide) or with combination chemotherapy which
includes drugs such as doxorubicin and vincristine. However.
eventually nearly all patients develop resistance to further
chemotherapy and die of the disease. The phenomenon of
MDR has been demonstrated in myeloma patients and cor-
related with response to chemotherapy (Dalton et al.. 1989:
Epstein et al., 1989).
In this study. we have examined the nature of the relation-
ship between the levels of expression in myeloma marrow
samples of the mdrl gene and two Glutathione S-Transferase
genes. GST-2 and GST-3.
Materials and metxods
Cell lines
In this study. mdrl mRNA levels are expressed relative to an
immortalised human T-cell line. CCRF-CEM cells. which is a
drug sensitive cell line orginally derived from an acute
lymphoblastic leukaemia. Two other cell lines were also
employed: the multidrug resistant cell lines. RIOO and R1000I
derivatives of CCRF-CEM cells which are resistant to 100
and 1,000 ng ml-i of vinblastine respectively. Both carry
amplifications of the mdrl gene and express mdrl mRNA at
high levels relative to their parent cell line (Woodcock et al..
1990). The cells were routinely cultured in the Alpha modi-
fication of Eagle's minimal essential medium containing 10%
new born bovine serum (Flow Laboratories. Australia). For
the first 5 days of each month, the resistant cell lines were
exposed to their respective concentration of vinblastine
(Velbe: Lilly).
Patient population
Forty-seven patients with multiple myeloma were studied.
Bone marrow biopsies were examined microscopically to
determine the degree of myeloma cell involvement and an
aspirate was provided for RNA extraction. Thirteen of the
patients had received previous treatment with an alkylating
agent (melphalan or cyclophosphamide) and prednisolone.
One of these patients also received the VAD regimen (con-
tinuous infusion vincristine plus adriamycin with oral dexa-
methasone) (Barlogie et al., 1984). Thirty-seven patients
received chemotherapy following the bone marrow biopsy.
The chemotherapy protocols used are shown in Table I. The
criteria for response were those recommended by the Chronic
Leukaemia Myeloma Task Force (1973) and required a
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reduction of serum and or urinary M-protein to less than
50% of the initial value sustained for a penrod of 1 month.
RNA extraction, slot blotting and hvbridisation
Mononuclear cells were isolated from heparinised bone
marrow aspirates on a Ficoll-Paque (Pharmacia) density
gradient. Total cellular RNA was isolated by lysing the cells
in 4M guanidine isothiocyanate followed by ultracentrifuga-
tion on a 5.7 M caesium chloride cushion (Chirgwin et al..
1979). RNA was dissolved in cold 10 mM NaOH, 1 mM
Table I Details of treatment. responses to treatment. and levels of
mdrl. GST-2 and GST-3 mRNAs
mdrl
1.99
0.88
3.3
1.1
1.04
2.4
1.96
0.96
0.77
l
1.9
1.08
1.23
1.3
4.06
1.04
0.66
0.51
0.47
2.32
2.65
3.5
1.71
6.71
9.4
2.87
0.89
1.2
1.56
1.36
6.17
33
20.17
5.1
121.6
19.71
2.81
1.6
2.06
3.3
1.32
1.63
1.94
2.43
0.64
3.31
0.61
1.04
1.56
1.4
3.58
11.7
1.06
1.48
Subsequent
GST-2 GST-3 treatment Response
0.74
0.36
0.97
1.7
0.91
0.91
1.4
1.4
0.84
1.26
0.41
1.5
1.21
0.84
1.29
1.0
0.69
0.93
4.54
6.07
11 1)
0.14 C+M+P
0.72 ABCP
0.45 M+P
0.71 M+P
- M+P
- M+P
- M+P
0.44 ABCP
0.77 ABCP
- M+P
- M+P
0.38 CHOP
0.54 M+P
- M+P
0.84 M+P
1.05 ABCP
0.28 M+P
0.52 M+P
0.23 M+P
0.33
0.15
0.5
1 .,,
1.37 0.33
1.37 1.05
1.7 0.33
1.10 0.83
- 1.44
29.4 -
5.0 -
5.12 2.2
3.24 1.51
1.70 0.79
1.3
2.24
1.66
0.87
1.08
2.14
0.95
3.57
1.42
1.25
1.28
2.3
3.26
1.99
1.63
0.78
0.28
0.58
0.17
1.38
1.38
0.89
2.22
1.05
0.97
0.42
0.43
2.71
0.25
2.09
M+P
M+P
M+ P
M + P
M+P
M+P
M+P
M + P ABCP
M + P
M+P
VCAP + VCN
M+P
ABCP
C+P
VBAP
D
M+P
ABCP
VAD
none
none
none
none
none
none
none
none
none
none
none
none
none
none
none
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
no
no
no
no
no
no
no
no
yes
yes
MP yes
no
no
no
no
no
Unknown
NA
NA
Abbreviations: NA, not assessable; C, cyclophosphamide; M, mel-
phalan; P, prednisolone; A, doxorubicin; B, BCNU; H, doxorubicin; V,
vincristine; D, dexamethasone. All mRNA levels are expressed relative
to that of the control cell line, CCRF-CEM. Sample numbers with a
suffix 'a', 'b', or 'c' represent estimates ofmRNA from repeat marrow
samples from an individual patient.
EDTA. Nylon filters were pre-soaked (Zeta-probe in distilled
water and Immobilon-N in methanol and distilled water) and
samples were applied to a Bio-Rad Slot Blot SF micro-
filtration apparatus. Dependent upon recoveries from the
patient samples, parallel slot blots were prepared with 10 g
and 0.1 fg of RNA per slot (the latter being 1 100 dilutions
from the 10 jig samples). Filters were prehybridised for at
least 1.5 h in 50% formamide, 0.5% blotto (Diplomat non-
fat milk powder), 2 x SSPE, 1% polyethylene glycol (6000
M.Wt., PEG), 8% sodium dodecyl sulfate (SDS) and 100 ytg
ml-' salmon sperm DNA at 500C. The filters with I0jg of
RNA per slot were then hybridised for about 17-20 h in the
same solution and temperature with random primer labelled
probe. After hybridisation the filters were washed twice at
room temperature for a total of 30 min in 2 x SSC, 0.10%
SDS followed by a 10 min wash at 5O°C in 0.2 x SSC, 1%
SDS. The filters were finally rinsed in 2 x SSC. The slots
blots with 0.1 tg of RNA per slot were hybridised with an
end-labelled 28S human ribosomal oligonucleotide probe to
adjust for total RNA loading from each sample. The
oligonucleotide prehybridisation (at least 30 min) and hybri-
disation (17-20 h) was carried out at 55°C in a solution
containing 3 x SSPE, 1% SDS. 1% PEG, 0.5% blotto.
Filters were washed twice for a total of 20 min at room
temperature in 3 x SSC. 0.1% SDS and once at 55°C for
30 min in 1 x SSC, 1% SDS which was followed by a rinse
in 1 x SSC, 0.1% SDS. Film was preflashed and exposures
within the linear range of the film were used for analysis on a
Zeineh soft laser scanning densitometer (Biomed Instruments.
Fullerton. CA).
Quantitation and standardisation ofmKVA levels
The mdrl probe, pHDR5a was kindly provided by M.
Gottesman and I. Pastan. The probe is a cDNA covering
1383 bp of the 4255 bp full length cDNA of the human mdrl
gene subcloned into the EcoRI site of pGEM4 (Fojo et al.,
1987). Clones for GST-2 and GST-3 were isolated from
human cDNA libraries (Board & Webb, 1987; Board et al..
1989). For the standardisation of RNA levels in each sample,
the initial blots were hybridised with an 18S rat ribosomal
probe (Woodcock et al.. 1990) whereas the later slot blots
were probed with a 28S rRNA oligonucleotide probe (Barbu
& Dautry, 1989). These latter two protocols gave equivalent
results.
To correct for any variation in the amounts of total RNA
in each sample, mdrl mRNA levels were standardised relative
to the amount of ribosomal RNA present. All results are
expressed relative to the mdrl mRNA levels in the drug
sensitive cell line, CCRF-CEM. A typical slot blot is shown
in Figure 1. R100 and RIOOO cells express p-glycoprotein 45
and 79-fold higher than the sensitive parent cell line (Wood-
cock et al., 1990).
Results
Details of patient response to chemotherapy are presented in
Table I. Of the 37 patients treated with chemotherapy, two
were too early to be assessable for response and one was lost
to follow-up. Seven of the 34 assessable patients had received
prior chemotherapy and 27 were newly diagnosed patients
previously untreated.
Levels ofmRNA for the mdrl gene were determined for all
myeloma marrow samples presented in Table I. These filters
containing total cellular RNA were rehybridised to determine
levels of mRNA for GST-2 and, thirdly, for GST-3 when the
additional probe became available. Successful estimations for
GST-2 were performed with samples from 46 of these 54
samples and, for GST-3, for 39 samples. Values of mRNA
levels for mdrl, GST-2 and GST-3 are presented in Figure 2
(A, B and C respectively) for responders and non-responders
according to prior treatment. Amongst the 27 evaluable
patients who had been untreated prior to the marrow biopsy,
the eight patients who failed to respond to initial
Prior
No. treatment
3 -
4
5
6 -
7 -
8
9 -
10
11 -
12 _
13 -
14 _
15 _
16 -
17 _
18 _
19 -
20 -
21
23 -
24
25
26
27 -
28 M+P
29 M+P
29a M + P
30 M+P
31 M+P
32 M+P
33 M+P
34 M+P
35 -
36 -
37 C+P
38
39 _
40 -
41 -
41a
41b -
42 -
8a ABCP
9a ABCP
16a ABCP
43 M +P,VAD
43a
44 M+P
45 M+P
46 C+P,M+P
47 M + P,V
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Figure 1 An autoradiogram of a representative slot blot. Col-
umns a. b and c were hybridised with the mdrl probe with a
nominal 10Ig of total RNA loaded per slot except for c2 and c4
With 1 gig. The lower loadings of RNA with these samples was to
avoid any potential problem of exceeding the linear range of the
film. RNAs loaded were from patient marrow samples except for
slots al and c2 to c5 which were from reference cell lines with
low and high mRNA levels which were included for quantitation
of relative expression levels. The other portion of the filter
(columns a'. b'. and c') was hybridised with the ribosomal probe
to give an independent estimate of relative amounts of total RNA
in each sample. In a'. b' and c', a nominal 0.1 gig of RNA was
immobilised in each slot (each X dilutions of the 10 gg samples).
All samples on these filters could be quantitated satisfactorily
with the exception of slot c'l with the ribosomal probe in which
the recovery of total RNA from the patient sample had been too
low.
chemotherapy had significantly higher mdrl mRNA levels
than for the 19 responders (Wilcoxon rank sum test.
P = 0.011). The same trend was seen amongst the eight sam-
ples from the evaluable patients who had received prior
treatment where the mdrl levels from the non-responders
were all higher than the mdrl levels from the responders
(P = 0.025).
Similarly, high GST-2 mRNA levels tended to be associat-
ed with a failure to respond both in previously untreated and
previously treated patients, but the differences were not
statistically significant (P =0.09 and P = 0.12 respectively).
possibly due to the small sample sizes involved (24 and four
patients respectively). Over the total group of myeloma
patients, mdrl and GST-2 mRNA levels were significantly
positive correlated (Spearman rank correlation coefficient
r = 0.54, P = 0.0004) (Figure 3a).
There was no apparent association between GST-3 mRNA
levels and response to chemotherapy and the correlation of
GST-3 with mdrl (r = 0.16. P = 0.4) was weak. However.
there was a strong correlation between GST-3 and GST-2
levels (r = 0.43, P = 0.017) (Figure 3b).
There was no apparent correlation of mdrl. GST-2, or
GST-3 levels with survival for previously untreated patients.
Patients exhibiting mRNA levels above or below the median
value were categorised as having high or low levels of expres-
sion respectively. Patients with low mdrl values had a median
survival of 22 months compared to a median survival of 26
months for the patients in the high mdrl category (P = 0.13,
log rank test). Likewise, patients with low and high GST-2
had median survivals of 25 and 22 months respectively
(P = 0.6), while patients with low and high GST-3 levels had
median survivals of 27 and 21 months (P = 0.2). In addition
to the lack of correlation between levels of expression of
these genes and survival, there was no correlation between
response to initial chemotherapy and survival in this patient
group with non-responder having a median survival of 26
months compared with 22 months for responders (P = 0.5).
Similar observations with respect to response and survival for
this tumour type have been made previously (Joshua et al.,
1991).
We have received more than one marrow sample from only
six patients in this series (Table I). With one exception (#8),
levels of expression of the genes tested were similar to that
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Fgre 2 Levels of mRNA in marrow samples from multiple
myeloma patients with assessable responses to chemotherapy for
A mdrl, B GST-2, and C GST-3 expressed relative to that in the
control cell line. CCRF-CEM cells. The patient data is divided
into (a) previously untreated patients responsive to subsequent
chemotherapy, (b) previously untreated patients not responsive to
subsequent chemotherapy, (c) previously treated patients respon-
sive to subsequent chemotherapy. and (d) previously treated
patients not responsive to subsequent chemotherapy. Because of
the wide spread of relative mRNA levels. values are plotted on a
logarithmic scale. Median values for the samples from patients in
the different categories are indicated for each section of the
figure. Median values for mdrl in the patient samples in the
different categories were (a) 1.08, (b) 2.76, (c) 1.36, and (d) 20.2.
Median values for GST-2 were (a) 1.00, (b) 1.37, (c) 1.4, and (d)
17.2 while, for GST-3, median values were (a) 0.52, (b) 0.33. (c)
0.58, and (d) 1.44.
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Figure 3 Graph of levels of mRNA for a mdrl plotted against
the level of GST-2 and b GST-2 against GST-3 for each of the
myeloma marrows for which both values had been successfully
quantitated. Only a single (usually initial) sample from each
patient is included in the analyses.
estimated in the initial samples. In patient #8, levels of
expression of all three genes rose from below the median
levels for untreated patients to well above this level subse-
quent to initial chemotherapy.
None of the genomic DNAs from multiple myeloma sam-
ples analysed by Southern blotting hybridised with the mdrl
probe showed evidence of amplification of the mdrl gene,
even in samples from tumours showing significantly higher
mRNA levels (P. Lockhart, unpublished observations). Simi-
lar observations have been made by Ito et al. (1989) with
acute leukaemia. Thus, while amplification of the mdrl gene
is common in multidrug resistant cell lines (reviewed by
Bradley et al., 1988), amplification of the mdrl gene does not
appear to be common after exposure to the lower drug
concentrations achieved in clinical situations.
D osso
A study of bone marrow aspirates from myeloma patients
using flow cytometry and indirect immunofluorescence with a
monoclonal antibody directed against the cytoplasmic domain
of p-170 positive cells has been shown to discriminate
between patients who are responsive and those who are
non-responsive to chemotherapy (Epstein et al., 1989). While
this methodology allows the identification of small subpopu-
lations of cells within a tumour which express high levels of
the P-glycoprotein, it has been reported to be relatively insen-
sitive for the detection of low levels of overexpression of the
mdrl gene (Stow & Warr, 1991). We have employed RNA
slot blotting and hybridisation with labelled probe (Chabner
& Gottesman, 1988). This method has the disadvantage of
assaying mdrl levels in a mixture of tumour and normal
marrow cells. However, we feel it is a more sensitive method
for the quantitation of lower levels of expression of genes in
mammalian cell populations. While this method cannot
detect the presence of small numbers of cells with higher
levels of expression than the average cell in the population.
antibody-based techniques would also be unlikely to detect
such subpopulations unless such cells showed high levels of
overexpression (Stow & Warr, 1991). We have used this
method to assay levels of expression of the mdrl gene as well
as the GST-2 and GST-3 genes and find that it gives a
reproducible and readily quantifiable signal.
The significant correlation between mdrl mRNA levels and
subsequent response to chemotherapy would suggest that
very elevated levels of mRNA for mdrl are likely to have
prognostic value for tumours which will prove refractory to
chemotherapy. However, there is significant overlap for
responders and non-responders in mdrl mRNA levels for
those tumours with intermediate values. Thus. for the indivi-
dual patient, quantitation of mdrl mRNA levels is likely to
be of only limited value for the prediction of subsequent
response to chemotherapy. However, there is a more funda-
mental question as to the clinical relevance of the estimation
of mdrl mRNA levels raised by these data.
The standard first line treatment for multiple myeloma at
our institute has been melphalan and prednisolone which
produces an objective response in approximately 50% of
patients. Patients not responding or relapsing following
initial treatment with melphalan and prednisolone are
often treated wth combination chemotherapy which includes
doxorubicin, BCNU, vincristine, cyclophosphamide and cor-
ticosteroids. Recent studies have suggested that similar com-
binations used as first line treatment will produce superior
results to melphalan plus prednisolone (Durie et al., 1986).
The drugs affected by the MDR phenotype are typically
plant alkaloids and antibiotics of fungal and bacterial origin
(Bradley et al., 1988). However, lower levels of cross-resis-
tance to alkylating agents have been reported. For instance.
in the multidrug resistant Chinese hamster ovary cell line
CHtC' which is 180-fold resistant to colchicine, there is a 4
to 15-fold increase in resistance to melphalan (reviewed by
Bradley et al., 1988). However, in other MDR cell types, no
collateral resistance to melphalan was found. Prednisolone
has not, to our knowledge, been reported to be affected by
the MDR phenotype. The majority of our patients received
melphalan plus prednisolone as primary chemotherapy
(Table I). The effectiveness of these drugs would not be
expected to be impaired significantly in tumours which exhi-
bit the MDR phenotype. Also chemotherapy with these
drugs would not be expected to provide any significant selec-
tive advantage for a tumour cell subpopulation which over-
expresses the mdrl gene. Yet, while expression levels of the
mdrl gene would seem to be irrelevant to the response of
tumours to melphalan and prednisolone, the data presented
here demonstrate that mdrl expression is significantly cor-
related with subsequent response to chemotherapy with these
agents in multiple myeloma.
The explanation for this apparent paradox seems to lie in
coordinate increases in expression of other pathways involved
in the detoxification of xenobiotics such as GST-2, an
enzyme with the ability to inactivate drugs such as melphalan
(Dulik et al., 1986). While our data strongly implicates the
GST-2 gene as one likely to be overexpressed together with
mdrl (and, in turn, GST-3 overexpressed with GST-2). it is
unlikly that these are the only cell stress-related genes which
may share similar responses to cellular insults. It should
Aw~~~~~~~~~qf%
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be noted that environmental stresses such as heat shock and
sodium arsenite exposure as well as hepatectomy increase
P-glycoprotein mRNA levels and will confer transient resis-
tance to vinblastine (Chin et al., 1990; Thorgeirsson et al.,
1987). Thus, increased expression of the mdrl gene and hence
the development of resistance to a wider variety of chemo-
therapeutic agents than those to which the tumour has been
directly exposed may be part of a cascade of cell stress-
inducible responses such as those demonstrated in the studies
of Scanlon et al. (1989) with cis-platinum resistant tumours.
The induction of such a cascade of damage-related gene
products might be an event triggered by the chemotherapy.
Alternatively, it may be a common event in the evolution
of tumours. providing a selective advantage through the
permanent activation of responses which normally function
only transiently under conditions of toxic or physical
insult.
In this relatively small number of myeloma patients. we
found that there was no association between response to
initial chemotherapy and survival. Similarly, Joshua et al.
(1991) have reported that there was no relationship between
percentage fall in paraprotein levels and survival. Survival in
that study was determined by the attainment of plateau
phase disease. It may be that current chemotherapy regimens
are selecting (or possibly even inducing) tumour cell sub-
populations with more aggressive growth characteristics. We
note that. of three patients (#8, #9. and #16) from whom
we have estimated mRNA levels for mdrl, GST-2 and GST-3
prior and then subsequent to initial chemotherapy, one of
them (#8) showed markedly increased levels of expression of
all three genes in the second marrow sample.
The second line chemotherapy used with multiple myeloma
patients who fail to respond to the primary therapy with
melphalan and prednisolone generally includes a number of
drugs which are affected by the MDR phenotype. Whatever
the mechanism leading to this common overexpression of the
mdrl gene and likely coordinate overexpression of other
genes such as GST-2 in these non-responsive patients. our
data would suggest that these patients who have a tumour
which has become resistant to the drugs used in primary
chemotherapy are very likely to give a poor response to the
drug combinations currently used in salvage chemotherapy.
In summary, while the MDR phenotype appears to be a
component of resistance of human tumours to chemotherapy.
it appears that what might be termed 'MultiPathway Resis-
tanc' (MPR) is likely to be more relevant to the clinical
situation.
We would like to thank M. Gottesman and I. Pastan for the mdrl
probe. K.H. Choo for the 18S ribosomal probe. and numerous
colleagues in various hospitals for providing us with patient samples.
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